APA (7th ed.) Citation

Wu, Y., Zhou, Y., Pan, Y., Jin, A., Meng, X., Li, H., . . . Wang, Y. (2025). Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA stratified by age and renal function: CHANCE-2 trial substudy. Renal Failure, 47(1), 1. https://doi.org/10.1080/0886022X.2025.2526684

Chicago Style (17th ed.) Citation

Wu, Yu, Yilun Zhou, Yuesong Pan, Aoming Jin, Xia Meng, Hao Li, Yilong Wang, Yong Jiang, and Yongjun Wang. "Ticagrelor Versus Clopidogrel in CYP2C19 Loss-of-function Carriers with Stroke or TIA Stratified by Age and Renal Function: CHANCE-2 Trial Substudy." Renal Failure 47, no. 1 (2025): 1. https://doi.org/10.1080/0886022X.2025.2526684.

MLA (9th ed.) Citation

Wu, Yu, et al. "Ticagrelor Versus Clopidogrel in CYP2C19 Loss-of-function Carriers with Stroke or TIA Stratified by Age and Renal Function: CHANCE-2 Trial Substudy." Renal Failure, vol. 47, no. 1, 2025, p. 1, https://doi.org/10.1080/0886022X.2025.2526684.